SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Închisă

SectorSănătate

115.5 1.49

Rezumat

Modificarea prețului

24h

Curent

Minim

113.8

Maxim

115.8

Indicatori cheie

By Trading Economics

Venit

215M

Vânzări

785M

P/E

Medie Sector

31.236

57.333

Randament dividend

0.79

Marjă de profit

11.32

Angajați

14,147

EBITDA

161M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+16.61% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.79%

2.63%

Statistici piață

By TradingEconomics

Capitalizare de piață

-117M

13B

Deschiderea anterioară

114.01

Închiderea anterioară

115.5

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

BioMerieux Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 apr. 2025, 08:49 UTC

Principalele dinamici ale pieței

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Comparație

Modificare preț

BioMerieux Așteptări

Obiectiv de preț

By TipRanks

16.61% sus

Prognoză pe 12 luni

Medie 133.17 EUR  16.61%

Maxim 140 EUR

Minim 127 EUR

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBioMerieux - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

113.8 / 118.9Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.